PPM and Inter Mohosot sign a MoU

On 31 March 2026, PPM Laboratory and Inter Mohosot Co., Ltd took a new step in their cooperation by signing a Memorandum of Understanding (MOU) for the exclusive distribution of nine PPM pharmaceutical products for a period of three years. The agreement was signed by Dr Hay Ly Eang, CEO of PPM Laboratory, and Mr Koy Borei, CEO of Inter Mohosot.

The nine products covered by the agreement are: Amitriptyline Hydrochloride 25 mg; Amlodipine Besylate Equivalent Amlodipine 5 mg; Amlodipine Besylate Equivalent Amlodipine 10 mg; Bromhexine HCL 8 mg; Domperidone 10 mg; Domperidone 5 mg; Prednisolone 5 mg; Atorvastatin 10 mg; and Ofloxacin 200 mg.

For Dr Hay Ly Eang, this MOU represents “only the first step”. The second step, he explained, will be to strengthen the market presence of PPM products in Cambodia through expanded distribution and greater outreach to healthcare professionals.

For his part, Mr Koy Borei expressed Inter Mohosot’s strong commitment to actively promoting PPM products. In his view, PPM and Inter Mohosot see themselves as genuine partners rather than a simple producer–buyer pair.

“We want to build a long-term journey with PPM. I hope that through this cooperation we will be able to gradually replace these products for imported medicines,” the CEO of Inter Mohosot said.